An interventional study of LH Suppression in Infertility, sponsored by Ibn Sina Hospital. Terminated at 3 sites in Egypt. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2022-06-15.
Sponsored by Ibn Sina Hospital · Not applicable, Interventional, and Treatment
Stimulation protocols for IVF underwent several cycles of upgrading aiming to achieve reasonable outcomes with low-cost cycles. Antagonist protocols have been introduced as effective and comparable to long agonist regarding the outcomes. However, these protocols are still costly. Alternative protocols using progestin suppressions appear options for consideration.
2,085 studies on the registry are indexed under Infertility; 357 are open to participants now.
This study's enrollment of 56 is below the median of 135 across 1,412 interventional studies indexed under Infertility.
Browse Infertility studies →Ibn Sina Hospital is the lead sponsor of 28 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dydrogesterone 30 mg on stimulation day 5 till the trigger day to prevent luteinizing hormone (LH) surge. The stimulation is with 150-300 IU FSH/HMG starting on cycle day 2 and adjusted according to the AFC and AMH.
Drug: LH Suppression
Dydrogesterone 30 mg on stimulation day 5 till the trigger day to prevent LH surge. The stimulation is with clomifene citrate 50 mg three times daily with150 IU FSH starting on cycle day 2 and continued every other day and adjusted according to the AFC and AMH.
Drug: LH Suppression
cetrorelix acetate 0.25 started on stimulation day 6 till the trigger day to prevent LH surge. The stimulation is with150-300 IU FSH starting on cycle day 2 and continued daily and adjusted according to the AFC and AMH.
Drug: LH Suppression
Stimulation protocols
Live Birth after first Vitrified-warmed cycle
Delivery of one or more viable infants \> 20th weeks of gestation
Time frame: 42 weeks of gestation
Biochemical pregnancy
positive human chorionic Gonadotrophin (βhCG) ≥ 10 IU/L
Time frame: 14 days after egg retrieval
Clinical pregnancy
registered sacs with a heartbeat on ultrasound at 7th weeks of gestation
Time frame: within 12 weeks of gestation
Ongoing pregnancy
continued viable pregnancy \> 20th weeks of gestation
Time frame: within 24 weeks of pregnancy
Miscarriage
loss of pregnancy ≤ 20th weeks of gestation
Time frame: Within 20 weeks of pregnancy
Term live-birth for vitrified-warmed transfer
Delivery of one or more viable infants ≥37 weeks of gestation
Time frame: Within 42 weeks of gestation
Preterm Birth
delivery of one or more viable infants \< 37th weeks of gestation
Time frame: Within 42 weeks of gestation
Very preterm birth
delivery of one or more viable infants \< 32nd weeks of gestation
Time frame: Within 42 weeks of gestation
Low birth weight babies
Babies with \< 2500 gm
Time frame: Within 24 hours of delivery
Congenital malformation
delivery of congenitally malformed babies
Time frame: Within one month of delivery
Still birth
delivery of nonviable babies \> 20 weeks of gestation
Time frame: Within 42 weeks of gestation
Cumulative live birth
Registered viable neonates after two vitrified-warmed transfers within one year of randomization
Time frame: One year from randomization
Fertilization
presence of 2 pronuclei 17±1 hr after oocyte injection
Time frame: Within 6 days of culture
Embryo cleavage
Cleaved embryos per fertilized oocyte
Time frame: Within 6 days of culture
Top-quality embryo on day 3
(7-8 cells with appropriate-sizes blastomeres and less than 10% fragmentation by volume
Time frame: Within 6 days of culture
Blastocyst formation on day 5 or 6
formed blastocysts per fertilized oocyte
Time frame: Within 6 days of culture
Top-quality blastocyst on day 5
Rounded and dense inner cell mass with many trophectodermal cells creating a connected zone and a blastocoel more than 100% by volume; ≥ 311 grade per fertilized oocyte
Time frame: Within 6 days of culture
Cryopreservation
Cryopreserved embryos per fertilized oocyte
Time frame: Within 6 days of culture
Live-birth-implantation rate
Number of viable neonates per number of embryos transferred
Time frame: Within 42 weeks of gestation
Utilized embryos
Number of cryopreserved plus transferred embryos per fertilized oocyte
Time frame: Within 6 days of culture
Top-quality utilized embryos
Number of high-quality embryos transferred plus cryopreserved per fertilized oocyte
Time frame: Within 6 days of culture
Metaphase II oocyte
Mature oocyte per oocyte collected
Time frame: Within 24 hours of oocyte retrieval
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2019 to primary completion in Apr 2020, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ibn Sina Hospital